The news of UBS maintaining a Buy rating on 89bio indicates a positive outlook for the company. However, the lowering of the price target from $36 to $25 suggests a potential downside, which might impact the stock's short-term performance. The overall impact is neutral as the positive and negative signals balance each other out.